Hilton, John
Gelmon, Karen
Bedard, Philippe L. http://orcid.org/0000-0002-6771-2999
Tu, Dongsheng
Xu, Hong
Tinker, Anna V.
Goodwin, Rachel
Laurie, Scott A.
Jonker, Derek
Hansen, Aaron R.
Veitch, Zachary W.
Renouf, Daniel J.
Hagerman, Linda
Lui, Hongbo
Chen, Bingshu http://orcid.org/0000-0001-6139-0696
Kellar, Deb
Li, Irene
Lee, Sung-Eun
Kono, Takako
Cheng, Brian Y. C. http://orcid.org/0000-0002-9258-8184
Yap, Damian http://orcid.org/0000-0002-5370-4592
Lai, Daniel http://orcid.org/0000-0001-9203-6323
Beatty, Sean http://orcid.org/0000-0001-6819-7071
Soong, John
Pritchard, Kathleen I.
Soria-Bretones, Isabel
Chen, Eric
Feilotter, Harriet
Rushton, Moira
Seymour, Lesley http://orcid.org/0000-0001-8081-0799
Aparicio, Samuel http://orcid.org/0000-0002-0487-9599
Cescon, David W. http://orcid.org/0000-0002-1080-0998
Article History
Received: 19 October 2021
Accepted: 7 June 2022
First Online: 24 June 2022
Competing interests
: John Hilton—Consulting: Merck, AZ, Novartis, Pfizer, Lilly, BMS; Research Funds: GSK, Lilly; DMC Committees: BMS. Karen Gelmon—Consulting/Advisory: AstraZeneca, Pfizer, Novartis, Lilly, Mylan, Merck, Gilead, Roche, Ayala, Nanostring, Genomic Health. Expert Testimony: Genentech. Research Funding: AstraZeneca, Pfizer, BMS, Roche. Philippe L. Bedard—Dr. Bedard reports grants from BristolMyersSquibb, Sanofi, Genentech/Roche, Novartis, GlaxoSmithKline, Nektar Therapeutics, Merck, Lilly, Servier, PTC Therapeutics, SeaGen, Mersana, Amgen, Zymeworks, VelosBio outside the submitted work; and Uncompensated advisory boards for BristolMyersSquibb, Sanofi, Pfizer, Genentech/Roche, Amgen, Lilly, SeaGen, Merck. Anna Tinker—Honoraria: AstraZeneca and Eisai; Grant/research funding: AZ. Rachel Goodwin—Speaker and Consultant: Merck, Pfizer, Bayer, Ipsen, Novartis (AAA), Eaisi, Amgen, Apobiologix. Research grant: Apobiologix, Ipsen, Novartis. Aaron R. Hansen—Consulting or Advisory Role: Merck, GlaxoSmithKline, Bristol Myers Squibb, Eisai. Research Funding: Karyopharm Therapeutics, Merck, Bristol Myers Squibb, Boehringer IIngelheim, GlaxoSmithKline, Roche/Genentech, Janssen, AstraZeneca/Medimmune, Astellas Pharma, Macrogenics. Zachary W. Veitch—has received honoraria from Pfizer and Genomic Health. Daniel J Renouf—Research funding and honoraria from Bayer and Roche, and travel funding and honoraria from Servier, Celgene, Taiho, Ipsen, and AstraZeneca. John Soong—Stockholder: Senhwa Biosciences. Kathleen Pritchard—Honoraria/Consulting: Pfizer, Roche, Amgen, Novartis, Eisai, Genomic Health Inc., Myriad Genetic Laboratories. Royalties: UpToDate. Lesley Seymour—Research support to CCTG from Senhwa Biosciences for the current work. Samuel Aparicio—SAp is a cofounder of Canexia Health Inc, Inflex Ltd, and scientific advisor to Sangamo Pharmaceuticals, Repare Pharmaceuticals. Funding: SAp is supported by Canada Research Chairs Program, Canada Foundation for Innovation. Work supported by StandUptoCancer, BC Cancer Foundation, Canadian Cancer Research Society, Canada Institutes for Health Research. David Cescon—Consulting/Advisory: AstraZeneca, Eisai, Exact Sciences, Gilead, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Research funding to institutions: AstraZeneca, Gilead, GlaxoSmithKline, Inivata, Merck, Pfizer, and Roche. Patent (US62/675,228) for methods of treating cancers characterized by a high expression level of spindle and kinetochore associated complex subunit 3 (ska3) gene. All other authors declare no potential conflicts of interest.